RPI-1, a novel 2-indolinone RET tyrosine kinase inhibitor, has shown promising results in sporadic papillary thyroid carcinomas with frequent RET alterations in vivo.375 The therapeutic effect was quite immediate, and tumor proliferation was efficiently controlled, with the tumor weight reduced to 20% of the control group. This evidence concerns the gene RET and neoplasm.